Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207686 | 0.84 | OPRM1 (0.62) | OPRM1OPRD1 | |
| SCHEMBL3207676 | 0.84 | OPRM1 (0.62) | OPRM1OPRD1 | |
| SCHEMBL1848310 | 0.74 | OPRM1 (0.66) | OPRM1OPRD1 | |
| SCHEMBL1848309 | 0.74 | OPRM1 (0.66) | OPRM1OPRD1 | |
| SCHEMBL25228929 | 0.72 | OPRM1 (0.49) | SLC18A3SIGMAR1OPRM1OPRD1 | |
| SCHEMBL17850381 | 0.67 | SLC18A3 (0.49) | SLC18A3SIGMAR1OPRM1OPRD1MEN1 | |
| SCHEMBL31574451 | 0.66 | ESR2 (0.58) | ESR2MEN1KMT2A | |
| SCHEMBL11714739 | 0.66 | ESR2 (0.58) | ESR2MEN1KMT2A | |
| SCHEMBL15317745 | 0.65 | OPRM1 (0.47) | SLC18A3SIGMAR1OPRM1OPRD1MEN1 | |
| SCHEMBL25237180 | 0.65 | OPRM1 (0.61) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SLC18A3 678/4885SIGMAR1 6/4885OPRM1 1/4885 |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SLC18A3 678/4885SIGMAR1 6/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.